Ovarian Cancer Research Alliance Community Partner

RSS News

  • Phase 2 Trial to Test Exercise as Way to Improve Quality of Life in Recurring Ovarian Cancer May 27, 2020
    A new Phase 2 clinical trial in Australia will assess whether exercise can improve the quality of life and physical function of women with recurring ovarian cancer who are on chemotherapy. Researchers at Griffith University recently were awarded a AU$884,172 grant (about $581,000) from the Medical Research Future Fund for this project. They will collaborate with teams at […]
  • SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer May 20, 2020
    Maintenance therapy with AstraZeneca’s Lynparza (olaparib) extended survival by more than one year in women with BRCA-mutated relapsed ovarian cancer, whose tumors responded to platinum-based chemotherapy, final results from the SOLO-2 Phase 3 clinical trial show. Trial findings, “Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) […]
  • Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial May 13, 2020
    Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease progression in women with advanced ovarian cancer who had responded to a first-line platinum-based chemotherapy plus Avastin, interim results from a Phase 2 trial show. These findings are in the presentation, “Phase II OVARIO study of niraparib + bevacizumab therapy […]
  • FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer May 12, 2020
    The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This indication also includes patients who have advanced fallopian tube or primary peritoneal cancer. HRD-positive tumors — present in one of every two women with advanced ovarian […]
  • STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show May 6, 2020
    STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. The findings were presented by Wendel Naumann, MD, principal investigator of the trial, in a recent virtual presentation at the American Association for Cancer Research (AACR) […]
  • FDA Approves Zejula as First-line Maintenance Therapy for Advanced Ovarian Cancer April 30, 2020
    The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA mutation status. This indication also includes patients with advanced fallopian tube or primary peritoneal cancer. The decision comes two months after FDA’s acceptance of a supplemental New Drug Application (sNDA), which […]
  • Ovarian Cancer Often More Advanced at Diagnosis in Rural Areas in US April 29, 2020
    Women living in rural areas in the U.S. are significantly more likely to have metastatic disease at the time of their ovarian cancer diagnosis than those living in metropolitan areas, a study of patients in three Midwest states found. This finding is likely not a consequence of travel time to reach a primary care provider. […]
  • First Advanced Cancer Patients Dosed With VT1021 in Trial’s Expansion Phase April 22, 2020
    A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer and other tumor types has dosed the first patients in its dose expansion stage. Early results are expected later this year. Roughly 75 adults will be enrolled in this stage of the trial (NCT03364400). Besides ovarian cancer, the other groups […]
  • Antibody-drug Conjugate XMT-1536 Shows Promise for Ovarian Cancer in Phase 1 Trial April 15, 2020
    Treatment with XMT-1536 appears to be safe, with promising responses shown in heavily pretreated patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma in a Phase 1 clinical trial. Mersana Therapeutics’ XMT-1536 is an antibody-drug conjugate that works by delivering a toxic compound specifically to cancer cells containing a protein called sodium-dependent phosphate transport […]
  • Partnership to Ensure Gene-modified Cell Therapies for Ovarian Cancer Trials April 8, 2020
    Senti Biosciences is working with RoosterBio to ensure a quality supply of its candidate gene-modified cell therapies for ovarian cancer and other solid tumors, with a goal of bringing them into clinical testing. These investigative therapies are based on the replacement, inactivation, or introduction of genes into cells that were cultivated or modified outside the body. The […]
  • Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending April 1, 2020
    Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of the study’s first part is ongoing. However, the treatment’s developer, NuCana, has decided not to continue with a planned second part to focus on trials in other cancers. Acelarin […]
  • GEN-1 Added to Chemo Improves Removal of Ovarian Tumors, Early Data Show March 25, 2020
    The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian cancer, according to initial results of the OVATION 2 study. Adding GEN-1 to neoadjuvant chemotherapy (given before surgery to shrink tumors) increased the proportion of patients with complete removal of their tumors through surgery. GEN-1, developed by Celsion Corporation, consists of […]
  • Cellular Recycling Genes Linked to Ovarian Tumor Formation in Mice, Study Shows March 23, 2020
    Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes the formation of ovarian cancer tumors, a study in mice has found. These findings support further investigation into the process of autophagy, which is often abnormal in ovarian cancer patients, as a potential target […]
  • China Reviewing Zejula as First-line Therapy for Ovarian Cancer March 20, 2020
    The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) be approved as first-line maintenance therapy for women with ovarian cancer who are responding to platinum-based chemotherapy, the company announced. The supplemental New Drug Application (sNDA), submitted to the China National Medical Products Administration (NMPA), is for women with advanced epithelial […]